Posted by Michael Wonder on 21 Jul 2022
Ultra-expensive SMA drug Zolgensma to get insurance benefits from August
21 July 2022 - Novartis' Zolgensma (onasemnogene abeparvovec), the world's most expensive drug yet to treat spinal muscular atrophy, will become reimbursable in August, the government said.
The government set the maximum reimbursement price of the treatment at 2 billion won ($1.52 million), but the out of pocket expense per patient will be only 5.98 million won ($4,558) with the national health insurance coverage.
